Sutro Biopharma, Inc. (NASDAQ: STRO) is a Healthcare company (Biotechnology) with a market capitalization of $148M. The Maz Rating grades it against the other companies in its sector.
Sutro Biopharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.92, Sutro Biopharma, Inc. trades at 3.3x sales. Over the last twelve months it generated about $45M of revenue and a net loss of $209M. It runs a gross margin of 94.4%, an operating margin of -255.2% and a net margin of -344.2%. It shows return on equity of 142.7%, return on invested capital of -88.5% and a free cash flow yield of -87.6%. On the balance sheet: a debt-to-equity ratio of -1.95 and a current ratio of 2.94. Over the past 52 weeks the share price ranged from $7.15 to $43.85, with a beta of 1.55.
Sutro Biopharma, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 18 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.